Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, September 30 at 2:00 PM EDT

Register Free →

Search

Top

Laulima Government Solutions, LLC FL 32826-3283 USA

UEI: SLED_FDF99804FE202B8A

Laulima Government Solutions, LLC FL 32826-3283 USA is a federal contractor, registered under UEI SLED_FDF99804FE202B8A. It has been awarded $18,297,374 across 2 federal contracts. Primary work spans Research and Development in Biotechnology (except Nanobiotechnology). Top awarding agencies include W4PZ USA Medical Rsch Acquis Act.

Contact Information

Registration and classification details

Registration

UEI Code

SLED_FDF99804FE202B8A

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

Laulima Government Solutions, LLC provides specialized technical and professional support services within the medical research sector. The company's core capabilities include the delivery of veterinary medicine support services and regulated activities support services, specifically tailored for hig...

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

W4PZ USA Medical Rsch Acquis Act$18.3M100%

Awards by NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)$18.3M100%

Awards by Agency Over Time

Awards by Place of Performance

Compete with Laulima Government Solutions, LLC FL 32826-3283 USA

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for Laulima Government Solutions, LLC FL 32826-3283 USA

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Join 750+ contractors already using CLEATUS

Open opportunities in Laulima Government Solutions, LLC FL 32826-3283 USA's top NAICS codes and agencies

ARPA-H Comprehensive Organ System Modeling in Outer Space (COSMOS) Innovative Solutions Opening

Solicitation # ARPA-H-SOL-26-165

The Advanced Research Projects Agency for Health (ARPA-H) is seeking proposals under solicitation ARPA-H-SOL-26-165 for the Comprehensive Organ System Modeling in Outer Space (COSMOS) initiative. This program aims to determine if microgravity in Low Earth Orbit (LEO) accelerates tissue aging across brain, cardiac, uterine, and kidney tissues compared to terrestrial rates. If the Tissue Aging Rate in Space (TARIS) is found to significantly exceed the Tissue Aging Rate on Earth (TAROE), the initiative intends to establish a high-throughput, autonomous drug screening platform in LEO to make biomedical research and development more cost-effective and faster than Earth-based methods. The project is structured into two sequential phases: a 27-month Phase I focused on establishing and validating microphysiological systems (MPS) to quantify aging rates, and a 15-month Phase II dedicated to developing age-related pathology models for pro-regenerative drug testing. Key requirements include the use of MPS or organoids for at least 75 percent of experimental samples, the creation of LEO twin experiments, and the establishment of a contractual partnership with at least one Fortune 100 biopharmaceutical company. The program schedule spans FY27 through FY30 and includes two planned space launches in months 39 and 41. Awards will be granted via multiple Other Transaction (OT) Agreements to the most advantageous proposers, including universities, non-profits, and businesses. Evaluation is based primarily on the innovation and feasibility of the technical approach, the potential to transform biomedicine, and the team's expertise in managing costs and schedules. Proposers must adhere to strict administrative requirements, including the BIOSECURE Act, NIH Genomic Data Sharing policies, and specific research security and cybersecurity disclosures. Full proposals are due by October 7, 2026.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

ARPA-H Emerging Health Innovators (EHI) Initiative

Solicitation # ARPA-H-SOL-26-150

The Advanced Research Projects Agency for Health (ARPA-H) Emerging Health Innovators (EHI) initiative, solicitation ARPA-H-SOL-26-150, is a mentorship program designed to identify and engage early-career investigators for cutting-edge biomedical, health, and community-engaged research. Eligible principal investigators must be within eight years of completing their first terminal degree. The program focuses on 16 specific topic areas and utilizes a two-step submission process, beginning with an anonymized solution summary due October 30, 2026, followed by full proposals due February 10, 2027. Awards are issued as Other Transaction (OT) agreements with a tentative start date of June 30, 2027. Each award has a total value not to exceed 1,050,000 dollars over a three-year period, consisting of a two-year base period capped at 700,000 dollars and an optional third year capped at 350,000 dollars. Funding is structured around a fixed-price milestone payment schedule, with 12 total quarterly milestones and payments processed through the Payment Management Services (PMS) system. Performance is monitored via monthly one-hour virtual reviews with the ARPA-H program team. Evaluation is based on technical merit, innovativeness, feasibility, and alignment with the ARPA-H mission, with a strong emphasis on risk mitigation and the potential to impact national health research.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

Imaging Biomarker Research & AnalysisThis subcontract focuses on the development and testing of imaging-based biomarkers designed to identify pancreatic cancer and its precursor lesions. Working in support of prime contractors on NIH and NCI research projects, the scope of work involves utilizing advanced imaging modalities including MRI, CT, PET, and endoscopic ultrasound to characterize lesions and establish specialized protocols for identifying high-risk patients. Because the work involves human subject research, all activities must be conducted under appropriate IRB approval. The primary deliverables for this engagement consist of finalized imaging biomarker protocols and comprehensive analyzed imaging datasets. This opportunity is categorized under NAICS code 541714 and is associated with the National Institutes of Health within the Department of Health and Human Services. Interested parties must note the response deadline of November 5, 2029, to participate in this research and analysis initiative.

National Institutes Of Health

POSTED

DEADLINE

in about 3 years

NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)

Solicitation # PAR-28-072

The National Institutes of Health National Eye Institute is offering a bi-phasic, milestone-driven award through the Translational Research Program for Therapeutics (PAR-28-072) to accelerate the transition of laboratory research into biological, pharmaceutical, or medical device therapies for visual system diseases. The program is structured into two phases: an R61 phase of up to two years focusing on preliminary data and lead optimization, and an R33 phase of up to four years dedicated to final preclinical development and the filing of an Investigational New Drug or Investigational Device Exemption application with the FDA. The total combined duration of both phases cannot exceed five years. Transition to the R33 phase is contingent upon the administrative assessment of satisfactory completion of SMART milestones, which must include required pre-submission feedback from the FDA. Budgetary limits for direct costs are generally capped at 500,000 dollars per year for the R61 phase and 1,000,000 dollars per year for the R33 phase. Applicants must provide a Target Product Profile, a Gantt chart, and an Intellectual Property Strategy, while ensuring compliance with Good Manufacturing Practices and Good Laboratory Practice standards. Evaluation is based on the importance of the research, rigor and feasibility of the approach, and the expertise of the investigators and their environment. Eligible applicants, including small businesses and other for-profit organizations, must maintain active registrations in the System for Award Management and eRA Commons, and all principal investigators must have a linked ORCID ID. Awardees are also required to implement cybersecurity incident reporting procedures and an incident response plan in accordance with HHS guidelines.

National Institutes Of Health

POSTED

DEADLINE

in about 3 years

Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)

Solicitation # PAR-28-056

The National Institutes of Health, under the Department of Health and Human Services, is soliciting applications for Research Units as part of the Pancreatic Cancer Detection Consortium. This initiative focuses on the early detection of pancreatic ductal adenocarcinoma and the characterization of precursor lesions to identify high-risk patients. Multi-disciplinary teams will be tasked with developing and testing molecular and imaging biomarkers, utilizing machine learning for biomarker discovery, and conducting validation studies. Additionally, these units will collect longitudinal biospecimens to build a comprehensive biorepository. The program emphasizes collaborative efforts, requiring Research Units to share data, ideas, and biospecimens within the consortium. This effort aligns with the NCI's scientific framework to improve screening for populations with genetic predispositions or family histories of the disease. Interested parties must submit their applications by the deadline of November 5, 2029, in accordance with solicitation number PAR-28-056.

National Institutes Of Health

POSTED

DEADLINE

in about 3 years

NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)

Solicitation # PAR-28-072

The National Eye Institute's Translational Research Program (TRP) aims to accelerate the transition of laboratory research into clinical therapeutics for visual system diseases. This program supports the development of pharmaceutical, biological, medical device, or combination therapies through a bi-phasic, milestone-driven award structure. All projects begin with an R61 phase for up to two years to support research with significant preliminary data. Successful projects may transition to an R33 phase for up to four years, focusing on final preclinical development, filing IND/IDE packages with the FDA, and designing future clinical trials. The combined duration of both phases cannot exceed five years. A critical requirement of this program is the establishment of SMART milestones for both phases, which must be specific, measurable, achievable, relevant, and time-bound. Applicants are encouraged to provide contingency plans to address potential delays in meeting these goals. The ultimate objective of the R33 phase is for recipients to either obtain an IND/IDE application or transition the product into clinical practice within the performance period. This solicitation, identified as PAR-28-072, is issued by the National Institutes of Health.

National Eye Institute

POSTED

DEADLINE

in about 3 years

Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)

Solicitation # PAR-28-056

The National Cancer Institute is soliciting applications for Research Units as part of the Pancreatic Cancer Detection Consortium to advance the early detection of pancreatic ductal adenocarcinoma and the characterization of precursor lesions. These multi-disciplinary teams will focus on developing and testing molecular and imaging biomarkers to identify high-risk patients and those with lesions likely to progress to cancer. Key research activities include the use of machine learning for biomarker discovery, conducting validation studies, and collecting longitudinal biospecimens for a centralized biorepository. Under solicitation PAR-28-056, the selected Research Units are required to engage in collaborative efforts, sharing data and biospecimens across the consortium. The initiative aligns with the NCI's scientific framework for pancreatic cancer by prioritizing the identification of patients who could benefit from early intervention based on genetic factors, family history, or existing precursor lesions. Applications for this federal opportunity are due by November 6, 2029.

National Cancer Institute

POSTED

DEADLINE

in about 3 years

UNifying Imaging with QUantum Entanglement (UNIQUE) Innovative Solutions Opening (ISO)

Solicitation # ARPA-H-SOL-26-162

The Advanced Research Projects Agency for Health (ARPA-H) has issued Innovative Solutions Opening (ISO) ARPA-H-SOL-26-162 for the UNifying Imaging with QUantum Entanglement (UNIQUE) program. This 18-month, two-phase initiative seeks to develop a new biomedical imaging paradigm by integrating anatomical, functional, and molecular data with quantum-derived observables and entangled 511 keV photon pairs. The scope is divided into two technical areas: TA1, which focuses on the physical systems required to generate and measure quantum observables in biomedical settings, and TA2, which focuses on the computational foundation, including AI-driven reconstruction and multimodal data fusion. ARPA-H anticipates awarding multiple Other Transaction (OT) Agreements to eligible entities, including universities, non-profit organizations, and businesses. For-profit organizations that exceed the NAICS 541714 SBA size standard of 1,000 employees are required to provide a meaningful cost share. The application process follows a two-stage submission cycle, with Solution Summaries due by late October 2026 and Full Proposals due by December 15, 2026, with a final response deadline of December 16, 2026. Full proposals must consist of three volumes covering technical and management plans, cost proposals, and administrative requirements. Evaluation is based on the innovation and feasibility of the technical approach, the expertise of the personnel, the potential to transform biomedicine, and cost reasonableness. Key requirements include compliance with HHS regulations on human stem cells, adherence to cybersecurity standards, and restrictions on gain-of-function research and funding for foreign entities in countries of concern. Awardees will be expected to provide monthly status reports and participate in semi-annual in-person PI review meetings.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

HUBBLE DRAFT Program Announcement (PA)

Solicitation # DARPA-PA-26-10_DRAFT

The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office is issuing a presolicitation notice for the HUBBLE program, which aims to develop an in-silico capability for mapping all protein-protein interactions. The goal is to create a comprehensive human interactome hypercatalog, demonstrating its utility by identifying novel diagnostic and therapeutic targets for conditions such as traumatic brain injury. The program is structured in two phases, with Phase 1 lasting 12 months and Phase 2 lasting 18 months. Key deliverables include the development of PPI fingerprinting capabilities, the capture of a minimal interactome for mild traumatic brain injury, and the generation of a massive PPI hypercatalog benchmarked against DARPA-provided experimental datasets. Awards will be issued as Other Transactions for Research under 10 U.S.C. 4021, meaning they are not subject to the Federal Acquisition Regulation or the Defense Federal Acquisition Regulations Supplement. Eligible applicants include large and small businesses, universities, research institutions, and nontraditional defense contractors. Proposers must be registered in the System for Award Management and maintain CMMC Level 1 compliance. Evaluation is based on technical comprehension, technical ability, and the reasonableness of the cost rough order of magnitude. Submissions must be made via DARPA's Broad Agency Announcement Tool, and all abstracts must remain unclassified.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

UNifying Imaging with QUantum Entanglement (UNIQUE) Proposers' Day

Solicitation # ARPA-H-SN-26-162

The Advanced Research Projects Agency for Health (ARPA-H), through its Health Science Futures Office, has issued Special Notice ARPA-H-SN-26-162 to announce the UNifying Imaging with QUantum Entanglement (UNIQUE) program. This initiative aims to establish a new biomedical imaging paradigm by utilizing quantum-derived observables, specifically entangled or quantum-correlated 511 keV photon pairs, to reveal disease biology that is currently invisible to existing imaging technologies. The program is divided into two technical areas: an Imaging Core focused on physical systems and quantum-aware detectors, and a second area focused on AI-driven reconstruction and fusion methods to integrate anatomical, functional, molecular, and quantum-derived information. To support this effort, a hybrid Proposers Day is scheduled for October 16, 2026, at 8:30am ET, held at the Executive Conference Center in Arlington, Virginia. This event is designed to provide technical details, promote teaming, and alert the scientific community to an upcoming Innovative Solutions Opening (ISO) that was scheduled for release by September 18, 2026. Interested parties are encouraged to use the provided Lightning Talk Template to showcase their capabilities and teaming goals. While this notice provides program goals and technical direction, it is issued for information and planning purposes and does not constitute a formal solicitation for proposals. The primary point of contact for the program is Program Manager Wilfred Ngwa.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

Request for Information (RFI) on Identifying Basic Research Challenges to Accelerate United States Biotechnology Leadership

Solicitation # 892431-26-RFI-0003

The Department of Energy Office of Science, under the Biological and Environmental Research program, issued Request for Information 892431-26-RFI-0003 on September 24, 2026. This RFI is intended for market research to identify critical basic research challenges and scientific bottlenecks necessary to transition from descriptive biology to predictive biosystems design. The initiative focuses on three primary science objectives: translating genetic code into biochemical functions, designing cells and metabolic pathways to control cellular operations, and developing multi-scale computational models to predict the performance of plants and microorganisms. The ultimate goal is to accelerate the production of bio-advantaged materials, chemicals, and fuels to strengthen United States biotechnology leadership. Interested stakeholders are requested to provide succinct responses not exceeding two pages in a machine-readable PDF format by October 15, 2026. Submissions should address near-term scientific bottlenecks occurring within three to five years, missing capabilities for scaling biosystems design, high-priority industrial application areas, and effective models for public-private partnerships. Responses must include the organization name and a point of contact and should be submitted to the DOE Biotech Input email with the specified subject line. This RFI is for planning purposes and does not constitute a solicitation or a promise to issue a contract; furthermore, the DOE will maintain unlimited rights to all submitted information, and no proprietary or classified data should be included.

Department Of Energy

POSTED

DEADLINE

Clinical Trial Support ServicesThe Clinical Trial Support Services subcontract for the National Institutes of Health under the Department of Health and Human Services focuses on the administrative and operational management of clinical trials for prime contractors operating NIH REACH Hubs. The scope of work includes managing patient recruitment, IRB coordination, clinical site management, and data collection. To qualify, providers must possess Good Clinical Practice certification and demonstrated experience with NIH-defined clinical trials and data management systems. Key deliverables for this engagement include patient data sets, clinical trial reports, and regulatory submission packages. The opportunity was posted on September 24, 2026, with a response deadline of November 10, 2026. This subcontract falls under NAICS code 541714.

National Institutes Of Health

POSTED

DEADLINE

in about 1 month

Immune Drivers of Autoimmune DiseaseThe National Institute of Allergy and Infectious Diseases seeks to support the Immune Drivers of Autoimmune Disease network to investigate the triggers and early mechanisms of autoimmunity in humans. The primary goal is to develop tools for risk prediction and staging, identify pre-clinical immune mechanisms, and utilize artificial intelligence and big data to prevent autoimmune diseases. This initiative emphasizes the creation of preclinical cohorts and the use of remote recruitment and sampling to advance medical research. The network will be managed by a Coordinating Center responsible for data harmonization, sample sharing, and the administration of an Infrastructure Opportunity Fund for collaborative research projects. This forecast, issued by the National Institutes of Health under the Department of Health and Human Services, establishes a framework for shared infrastructure and steering committee oversight to identify common pathways and prevention opportunities.

National Institutes Of Health

POSTED

DEADLINE

Partnerships for Advancing Development of Diagnostics for Infectious DiseasesThe National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is seeking to establish partnerships between academic or small business investigators and industrial partners to advance the translational development of diagnostic tests for infectious diseases. This initiative focuses on moving diagnostics that have already demonstrated proof-of-concept through the commercialization process by aligning researchers with experienced industry partners to de-risk development and ensure products are fit for purpose. The program will be supported by a science advisory board and NIAID oversight, incorporating annual meetings and workshops to facilitate collaboration and knowledge exchange. This effort is authorized under the Public Health Service Act and federal regulations to ensure that promising diagnostic technologies are successfully translated into tools for treating and preventing infectious diseases.

National Institutes Of Health

POSTED

DEADLINE

The Role of the Innate Immune System in the Pathogenesis of Type 1 DiabetesThe National Institute of Allergy and Infectious Diseases, under the Department of Health and Human Services, is forecasting a grant opportunity to investigate the role of the innate immune system in the initiation of Type 1 Diabetes. Funded by the Special Statutory Funding Program for Type 1 Diabetes Research, this initiative seeks to identify genetic and environmental causes of the disease by examining how innate immune components interact with beta cells and pancreatic tissues. The program emphasizes the use of new approach methodologies to determine the timing and impact of environmental triggers that activate these immune pathways. The primary objective is to improve the early identification of high-risk individuals and develop future prevention and therapeutic strategies. This effort is conducted under the authority of the Public Health Service Act and relevant federal regulations. Interested parties can contact the RISP-T1D point of contact for further information regarding this forecast.

National Institutes Of Health

POSTED

DEADLINE

Limited Competition: NIH Research Evaluation and Commercialization Hubs (REACH) (SB0 Clinical Trial Optional)

Solicitation # RFA-OD-27-009

The National Institutes of Health (NIH) has issued Notice of Funding Opportunity RFA-OD-27-009 to renew the Research Evaluation and Commercialization Hub (REACH) program. This limited competition aims to establish academic entrepreneurship Hubs that accelerate the translation of biomedical discoveries into commercial products to improve public health and patient care. Funded Hubs will provide innovators with initial investment, mentorship in product development, and resources for proof-of-concept work, including product definition studies such as feasibility and prototype development. The program focuses on diverse technology areas, including small molecule therapeutics, biologics, medical devices, and health IT software, each with specific maturity requirements. The NIH intends to commit an estimated total of 20 million dollars to fund up to five awards over a maximum project period of four years, with a maximum budget of 1 million dollars in total costs per year per Hub. Each Hub is expected to fund at least five technology development projects, providing up to 100,000 dollars in direct costs per project. While not required, Hubs are highly encouraged to secure 250,000 dollars in annual non-federal matching funds. Applications are due by November 10, 2026, and will be evaluated through a standard peer-review process based on the importance of the research, rigor and feasibility of the operating model, and the expertise of the investigators and environment. Eligible organizations must maintain active registrations in the System for Award Management (SAM) and eRA Commons.

National Institutes Of Health

POSTED

DEADLINE

in about 1 month

Limited Competition: NIH Research Evaluation and Commercialization Hubs (REACH) (SB0 Clinical Trial Optional)

Solicitation # RFA-OD-27-009

The National Institutes of Health Office of the Director is offering a limited competition funding opportunity under solicitation RFA-OD-27-009 to renew the Research Evaluation and Commercialization Hub (REACH) program. This initiative aims to accelerate the translation of academic biomedical discoveries into tangible products that enhance public health and patient care by funding the creation of academic entrepreneurship Hubs. These Hubs will provide innovators with essential seed investment, mentorship in product development, and resources for proof-of-concept work to advance high priority technologies aligned with the NIH mission. Selected Hubs will operate as a consortium to establish infrastructure for identifying promising technologies and provide funding for product definition studies, such as prototype development and feasibility research. They will also offer expertise in regulatory, business, legal, and project management areas while fostering skills in entrepreneurship. Success in this program relies heavily on the establishment of public-private partnerships and the acquisition of non-federal funding. Eligible organizations must submit their applications by November 11, 2026, and will undergo a standard peer-review process to determine merit for funding.

National Institutes Of Health Office Of The Director

POSTED

DEADLINE

in about 2 months

Clinical/Biological Research ConsultantThis subcontract opportunity is for a Clinical/Biological Research Consultant to support prime contractors on Department of Defense SBIR/STTR Phase I projects. The selected consultant will design and execute research studies involving human or animal subjects within approved clinical environments or specialized laboratories, ensuring all work adheres to strict ethical and regulatory standards. Key deliverables include subject-specific research data and all necessary compliance documentation, with a mandatory requirement for IRB or IACUC approvals. The project is managed by the Office of the Secretary of Defense and is designated as a Total Small Business Set-Aside, requiring the contractor to have fewer than 500 employees. Falling under NAICS code 541714, the solicitation was posted on September 23, 2026, with a response deadline of October 7, 2026.

Office of the Secretary of Defense

POSTED

DEADLINE